Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Hepatocyte-specific IKK-β activation enhances VLDL-triglyceride production in APOE*3-Leiden mice.

van Diepen JA, Wong MC, Guigas B, Bos J, Stienstra R, Hodson L, Shoelson SE, Berbée JF, Rensen PC, Romijn JA, Havekes LM, Voshol PJ.

J Lipid Res. 2011 May;52(5):942-50. doi: 10.1194/jlr.M010405. Epub 2011 Feb 28.

2.

Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production.

Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K.

Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1287-98. doi: 10.1152/ajpgi.90540.2008. Epub 2009 Apr 2.

3.

Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia.

Huang Y, Liu XQ, Rall SC Jr, Taylor JM, von Eckardstein A, Assmann G, Mahley RW.

J Biol Chem. 1998 Oct 9;273(41):26388-93.

4.

Targeted deletion of hepatocyte ABCA1 leads to very low density lipoprotein triglyceride overproduction and low density lipoprotein hypercatabolism.

Chung S, Timmins JM, Duong M, Degirolamo C, Rong S, Sawyer JK, Singaraja RR, Hayden MR, Maeda N, Rudel LL, Shelness GS, Parks JS.

J Biol Chem. 2010 Apr 16;285(16):12197-209. doi: 10.1074/jbc.M109.096933. Epub 2010 Feb 23.

5.

Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice.

Mensenkamp AR, van Luyn MJ, van Goor H, Bloks V, Apostel F, Greeve J, Hofker MH, Jong MC, van Vlijmen BJ, Havekes LM, Kuipers F.

J Hepatol. 2000 Aug;33(2):189-98.

PMID:
10952236
6.

Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.

Grefhorst A, Elzinga BM, Voshol PJ, Plösch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F.

J Biol Chem. 2002 Sep 13;277(37):34182-90. Epub 2002 Jul 3.

7.

FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver.

Kim DH, Zhang T, Lee S, Calabuig-Navarro V, Yamauchi J, Piccirillo A, Fan Y, Uppala R, Goetzman E, Dong HH.

Endocrinology. 2014 Apr;155(4):1255-67. doi: 10.1210/en.2013-1856. Epub 2014 Jan 17.

8.

Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.

van Dijk KW, van Vlijmen BJ, de Winther MP, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH.

Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2945-51.

9.

Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet.

van Diepen JA, Vroegrijk IO, Berbée JF, Shoelson SE, Romijn JA, Havekes LM, Rensen PC, Voshol PJ.

Am J Physiol Endocrinol Metab. 2011 Dec;301(6):E1099-107. doi: 10.1152/ajpendo.00185.2011. Epub 2011 Aug 23.

10.

Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides.

de Beer F, van Dijk KW, Jong MC, van Vark LC, van der Zee A, Hofker MH, Fallaux FJ, Hoeben RC, Smelt AH, Havekes LM.

Arterioscler Thromb Vasc Biol. 2000 Jul;20(7):1800-6.

11.

Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis.

Huang Y, Ji ZS, Brecht WJ, Rall SC Jr, Taylor JM, Mahley RW.

Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):2952-9.

12.

Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor.

van Dijk KW, van Vlijmen BJ, van der Zee A, van't Hof B, van der Boom H, Kobayashi K, Chan L, Havekes LM, Hofker MH.

Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):7-12.

13.

Mice expressing only the mutant APOE3Leiden gene show impaired VLDL secretion.

Mensenkamp AR, Teusink B, Baller JF, Wolters H, Havinga R, van Dijk KW, Havekes LM, Kuipers F.

Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1366-72.

14.

Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes.

Kuipers F, Jong MC, Lin Y, Eck M, Havinga R, Bloks V, Verkade HJ, Hofker MH, Moshage H, Berkel TJ, Vonk RJ, Havekes LM.

J Clin Invest. 1997 Dec 1;100(11):2915-22.

15.

Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver.

Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, Voshol PJ, Hofker MH, van Dijk KW, Havekes LM, Kuipers F.

J Biol Chem. 1999 Dec 10;274(50):35711-8.

16.

Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity.

Duivenvoorden I, Teusink B, Rensen PC, Kuipers F, Romijn JA, Havekes LM, Voshol PJ.

J Lipid Res. 2005 May;46(5):988-93. Epub 2005 Feb 16.

17.

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL.

J Clin Invest. 1992 Nov;90(5):1889-900.

18.

SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes.

Li X, Li Y, Yang W, Xiao C, Fu S, Deng Q, Ding H, Wang Z, Liu G, Li X.

J Steroid Biochem Mol Biol. 2014 Sep;143:174-82. doi: 10.1016/j.jsbmb.2014.02.009. Epub 2014 Feb 22.

PMID:
24565561
19.

Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.

Berbée JF, van der Hoogt CC, Sundararaman D, Havekes LM, Rensen PC.

J Lipid Res. 2005 Feb;46(2):297-306. Epub 2004 Dec 1.

Supplemental Content

Support Center